Evaluation of Helicobacter pylori OipA protein as a vaccine candidate and propolis as an adjuvant in C57BL/6 mice

Document Type : Original Article


1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

2 Microbiology Department, Faculty of Biological Sciences, Alzahra University, Tehran, Iran

3 Medicinal Plants Research Department, Research and Development, TabibDaru Pharmaceutical Company, Kashan, Iran

4 Biotechnology Department, Faculty of Biological Sciences, Alzahra University, Tehran, Iran


Objective(s): Outer inflammatory protein A (OipA) is an essential adhesin of Helicobacter pylori. We aimed to evaluate the effects of a recombinant OipA in the induction of crucial cytokines as a vaccine candidate and propolis as an adjuvant in C57BL/6 mice.
Materials and Methods: C57BL/6 mice were divided into nine groups according to the disposition of antigen and adjuvant and route of administration: subcutaneous (sc) or gavage. The administrated recombinant purified OipA and propolis concentrations were 10 μg/ml and 40 μg/ml, respectively. After vaccination, we measured expression levels of IFN-γ and IL-4 cytokine genes in the spleen cells of mice by real-time PCR.
Results: All results were contrasted with the negative sample. By sc injection, the expression of INF-γ was increased 3.5 and 2.9-fold for OipA and OipA plus propolis, respectively. By gavage 4.4 and 11-fold increase was found for OipA and OipA plus propolis, respectively. The administration of propolis by gavage showed more increase than Sc injection concerning the production of INF-γ. The 11-fold increase for injection of OipA plus propolis by gavage was comparable OipA plus Freund’s adjuvant injected subcutaneously. This result suggested an excellent immunological response toward OipA concerning the production of INF-γ in mice. In all cases there were no notable IL-4 production increases.
Conclusion: The results confirm the efficiency of OipA in induction of IFN-γ production, and thereby the cellular immune response. Propolis could be a suitable adjuvant.


1. Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 2009; 3:81-87.
2. Dossumbekova A, Prinz C, Gerhard M, Brenner L, Backert S, Kusters JG, et al. Helicobacter pylori outer membrane proteins and gastric inflammation. Gut 2006; 55:1360-1361.
3. Sayi A, Kohler E, Hitzler I, Arnold I, Schwendener R, Rehrauer H, et al. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009; 182:7085-7101.
4. Wroblewski LE, Peek RM, Jr., Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23:713-739.
5. Mahboubi M, Falsafi T, Sadeghizadeh M. Cloning and Sequence Analysis of Gene Encoding OipA from Iranian Clinical Helicobacter pylori. Iran J Biotechnol 2014; 12:10-16.
6. Shi, Shuting, et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 2019; 37: 3167-3178.
7. Müller A, Solnick JV. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter 2011; 16:26-32.
8. Chonwerawong M, Avé P, Huerre M, Ferrero RL. Interferon-γ promotes gastric lymphoid follicle formation but not gastritis in Helicobacter-infected BALB/c mice. Gut Pathogen 2016; 8:61-70.
9. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001;19:523-563.
10. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 2007; 12: 89-102.
11. Fouladi M, Sarhadi S, Tohidkia M, Fahimi F, Samadi N, Sadeghi J, et al. Selection of a fully human single domain antibody specific to Helicobacter pylori urease. Appl Microbiol Biotechnol 2019;103:3407-3420.
12. Hirota K, Nagata K, Norose Y, Futagami S, Nakagawa Y, Senpuku H, et al. Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production. Infect Immun 2001; 69:6597-6603.
13. Takeshita H, Watanabe E, Norose Y, Ito Y, Takahashi H. Neutralizing antibodies for Helicobacter pylori urease inhibit bacterial colonization in the murine stomach in vivo. Biomed Res 2019;40:87-95.
14. Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine 2012; 31:120-126.
15.   Khastar, A., Farzin, H., Jamshidian-Mojaver, M. Evaluation of Cholera toxin Adjuvanticity Effect on the Production of Specific Antibodies Induced by Avian Infectious Bronchitis Vaccine in Chickens. Archives of Razi Institute 2021.
16. Byoung-Shik sh, In Su Ch, Eugene L, Sung-Moo P, Youngjoo C, Dae-Im J, et al. Development of safe and non-self-immunogenic mucosal adjuvant by recombinant fusion of cholera toxin A1 subunit with protein transduction domain. J Immunol Res 2018;2018:9830701.
17. Terrinoni M. Novel approaches to mucosal vaccine development Strategies in vaccine antigen production, construction of a novel mucosal adjuvant and studies of its mode of action. Doctoral thesis. University of Gothenburg. Sahlgrenska Academy; 2019.
18. Park SJ, Chun SK, Kim PH. Intraperitoneal delivery of cholera toxin B subunit enhances systemic and mucosal antibody responses. Mol Cells 2003;16:106-112.
19. van Splunter M, van Hoffen E, Floris-Vollenbroek EG, et al. Oral cholera vaccination promotes homing of IgA+ memory B cells to the large intestine and the respiratory tract. Mucosal Immunol 2018;11:1254-1264.
20.  Holmgren J. An update on cholera immunity and current and future cholera vaccines. Trop Med Infect Dis 2021; 6:64.
21. Raghava Mohan V, Raj S, Dhingra MS, et al. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India. PLoS One 2019;14: 0218033.
22. Tabassam FH, Graham DY, Yamaoka Y. OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization. Cell Microbiol 2008;10:1008-1020.
23. Akhiani AA, Schön K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J Immunol 2004;173:3348-3356.
24. Yamaoka Y, Kikuchi S, El–Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterol 2002; 123:414-424.
25. Mahboubi M, Falsafi T, Sadeghizadeh M, Mahjoub F. The role of outer inflammatory protein A (OipA) in vaccination of theC57BL/6 mouse model infected by Helicobacter pylori. Turk J Med Sci 2017; 47:326-333.
26. Fischer G, Paulino N, Marcucci MC, Siedler BS, Munhoz LS, Finger PF, et al. Green Propolis phenolic compounds act as vaccine adjuvants, improving humoral and cellular responses in mice inoculated with inactivated vaccines. Mem Inst Oswaldo Cruz 2010; 105:908-913.
27. Soumaya T, Walaa E, Hamada I, Abdalsalam K, Sleman K, Hilal Z, et al. In vitro evaluation of the potential use of propolis as a multitarget therapeutic product: Physicochemical properties, chemical composition, and immunomodulatory, antibacterial, and anticancer properties. BioMed Res Int 2019;2019:4836378.
28. Bankova VS, Castro SLd, Marcucci MC. Propolis: recent advances in chemistry and plant origin. Apidologie 2000; 31:3-15.
29. El-khawaga OA, Salem TA, Elshal MF. Protective role of Egyptian Propolis against tumor in mice. Clin Chim Acta 2003;338:11-16.    
30. Hegazi AG, Abd El Hady FK, Shalaby HA. An in vitro effect of Propolis on adult worms of Fasciola gigantica. Vet Parasitol 2007;144:279-286.
31. Soufy H, El-Beih N, Nasr S, El-Aziz T, Khalil F, Ahmed Y, et al. Effect of egyptian propolis on cryptosporidiosis in immunosuppressed rats with special emphasis on oocysts shedding, leukogram, protein profile and ileum histopathology. Asian Pac J Trop Med 2017;10:253-262.
32. Wei X, Koo I, Kim S, Zhang X. Compound identification in GC-MS by simultaneously evaluating the mass spectrum and retention index. Analyst 2014;139:2507-2514.
33. Burdock GA. Review of the biological properties and toxicity of bee Propolis (Propolis). Food Chem Toxicol 1998; 36:347-363.
34. Chang CC, Yang MH, Wen HM, Chern JC. Estimation of total flavonoid content in propolis by two complementary colorimetric methods. J Food Drug Analysis 2002; 10:178-182.
35. Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother 2013;4:303-306.
36. Soudi H, Falsafi T, Gharavi S, Mahboubi M. The role of Helicobacter pylori proinflammatory outer membrane protein and propolis in immunomodulation on U937 macrophage cell model. Galen Med J 2020; 1-9.
37. O’Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. Alkyl hydroperoxide reductase: A candidate Helicobacter pylori vaccine. Vaccine. 2012;30:3876-3884.
38. Algood HM, Cover TL. Helicobacter pylori persistence: An overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev 2006;19:597-613.
39. Attaran B, Falsafi T, Moghaddam AN. Study of biofilm formation in C57Bl/6J mice by clinical isolates of Helicobacter pylori. Saudi J Gastroenterol 2016;22:161-168.
40. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012;30:5310-5315.
41. Chen J, Li N, She F, Helicobacter pylori outer inflammatory protein DNA vaccine-loaded bacterial ghost enhances immune protective efficacy in C57BL/6 mice. Vaccine 2014; 32:6054- 6060.
42. Sforcin JM. Propolis and the immune system: A review. J Ethnopharmacol 2007; 113:1-14.    
43. Fischer G, Paulino N, Marcucci MC, et al. Green propolis phenolic compounds act as vaccine adjuvants, improving humoral and cellular responses in mice inoculated with inactivated vaccines. Mem Inst Oswaldo Cruz. 2010;105:908-913.
44.  Breen EC, McDonald M, Fan J, Boscardin J, Fahey JL. Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virus-infected persons. Clin Diagn Lab Immunol 2000;7:769-773.
45. Ansorge S, Reinhold D, Lendeckel U. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch C J Biosci 2003;58:580-589.
46. Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Díaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics 2006;117:878-886.
47. Raghavan S, Ostberg AK, Flach CF, et al. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect  Immun 2010;78:4251-4260.
48. Zhang JY, Liu T, Guo H, Liu XF, Zhuang Y, Yu S, et al. Induction of a Th17 cell response by Helicobacter pylori Urease subunit B. Immunobiol 2011;216:803-810.
49. Blonska M, Bronikowska J, Pietsz G, Czuba ZP, Scheller S, Krol W. Effects of ethanol extract of Propolis (EEP) and its flavones on inducible gene expression in J774A.1 macrophages. J Ethnopharmacol 2004;91:25-30.
50. Ansorge S, Reinhold D, Lendeckel U. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch C J Biosci 2003; 58:580-589.
51.  Sá-Nunes A, Faccioli LH, Sforcin JM. Propolis: lymphocyte proliferation and IFN-gamma production. J Ethnopharmacol 2003; 87:93-97.